Literature DB >> 29952740

Human Vaccines & Immunotherapeutics: News.

.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29952740      PMCID： PMC6037458          DOI： 10.1080/21645515.2018.1476960

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  7 in total

1.  Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

Authors:  Angela Huttner; Selidji Todagbe Agnandji; Christophe Combescure; José F Fernandes; Emmanuel Bache Bache; Lumeka Kabwende; Francis Maina Ndungu; Jessica Brosnahan; Thomas P Monath; Barbara Lemaître; Stéphane Grillet; Miriam Botto; Olivier Engler; Jasmine Portmann; Denise Siegrist; Philip Bejon; Peter Silvera; Peter Kremsner; Claire-Anne Siegrist
Journal:  Lancet Infect Dis       Date:  2018-04-05       Impact factor: 25.071

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Nanoemulsion adjuvant-driven redirection of TH2 immunity inhibits allergic reactions in murine models of peanut allergy.

Authors:  Jessica J O'Konek; Jeffrey J Landers; Katarzyna W Janczak; Rishi R Goel; Anna M Mondrusov; Pamela T Wong; James R Baker
Journal:  J Allergy Clin Immunol       Date:  2018-04-11       Impact factor: 10.793

4.  AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression.

Authors:  Binghao Li; Yang Zeng; Patrick M Reeves; Chongzhao Ran; Qiuyan Liu; Xiying Qu; Yingying Liang; Zhao Liu; Jianping Yuan; Pierre R Leblanc; Zhaoming Ye; Ann E Sluder; Jeffrey A Gelfand; Timothy A Brauns; Huabiao Chen; Mark C Poznansky
Journal:  Cancer Immunol Res       Date:  2018-03-06       Impact factor: 11.151

5.  Predicting Influenza H3N2 Vaccine Efficacy From Evolution of the Dominant Epitope.

Authors:  Melia E Bonomo; Michael W Deem
Journal:  Clin Infect Dis       Date:  2018-09-14       Impact factor: 9.079

6.  Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Authors:  Janos L Tanyi; Sara Bobisse; Eran Ophir; Sandra Tuyaerts; Annalisa Roberti; Raphael Genolet; Petra Baumgartner; Brian J Stevenson; Christian Iseli; Denarda Dangaj; Brian Czerniecki; Aikaterini Semilietof; Julien Racle; Alexandra Michel; Ioannis Xenarios; Cheryl Chiang; Dimitri S Monos; Drew A Torigian; Harvey L Nisenbaum; Olivier Michielin; Carl H June; Bruce L Levine; Daniel J Powell; David Gfeller; Rosemarie Mick; Urania Dafni; Vincent Zoete; Alexandre Harari; George Coukos; Lana E Kandalaft
Journal:  Sci Transl Med       Date:  2018-04-11       Impact factor: 17.956

7.  Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.

Authors:  Brendan Flannery; Jessie R Chung; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Angie Foust; Wendy Sessions; LaShondra Berman; John R Barnes; Sarah Spencer; Alicia M Fry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-02-16       Impact factor: 17.586
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.